Recruiting

LDRT

Sponsor:

Abramson Cancer Center at Penn Medicine

Code:

NCT07715188

Conditions

Osteoarthitis

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Low Dose Radiation Therapy

Study Details

Brief summary:

This single institution, multi-site, single arm prospective study will enroll patients with a history of OA and assess changes in pain and function after treatment with LDRT as measured by patient-reported outcomes.

Conditions

Osteoarthitis

Study ID

NCT07715188

Start date

Jun 24, 2026

Status verified date

Jul, 2026

Completion date

Jun, 2029

Anticipated

Primary completion date

Jun, 2029

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • 18 years or older
  • Diagnosis of OA >3 months in hips, knees, hands, shoulders, ankles or elbows.
  • Refractory to standard of care therapies for OA or those who are being considered for more aggressive interventional treatment such as joint replacement, but more conservative treatment is desired.
  • Provision of signed and dated informed consent.

Exclusion Criteria:

  • Unable to reasonably complete study instruments.

Study Design

Enrollment

113 participants

Anticipated

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

other: Single

Participants will complete study intervention which consists of the BPI-SF, PROMIS Global v1.2, UEFI (for those with joint pain of the upper extremity) and/or LEFS (for those joint pain of the lower extremity) at baseline, 3-month and 1-year follow-up following 1 or 2 courses of standard of care LDRT.

Interventions

Low Dose Radiation Therapy

Participants will complete study intervention which consists of the BPI-SF, PROMIS Global v1.2, UEFI (for those with joint pain of the upper extremity) and/or LEFS (for those joint pain of the lower extremity) at baseline, 3-month and 1-year follow-up following 1 or 2 courses of standard of care LDRT.

Primary outcome measure

  • To measure the percentage of subjects who experience a best response of 1 point or more on BPI-SF [ Time Frame: Within 1 year ]

Central Contacts and Locations

Central contacts

Marlowe Estioko, BS, MS

267-343-6483Marlowe.Estioko@Pennmedicine.upenn.edu

Sonya George, BS

267-760-7636Sonya.George@PennMedicine.upenn.edu

Locations

Penn Presbyterian Medical Center

Recruiting

Philadelphia, Pennsylvania, United States, 19104

Contacts

Marlowe Estioko, BS, MS

267-343-6483Marlowe.Estioko@Pennmedicine.upenn.edu

Sonya George, BS

267-760-7636Sonya.George@PennMedicine.upenn.edu

Principal Investigator:

John Plastaras, MD, PhD

Perelman Center for Advanced Medicine

Recruiting

Philadelphia, Pennsylvania, United States, 19104

Contacts

Marlowe Estioko, BS, MS

267-343-6483Marlowe.Estioko@Pennmedicine.upenn.edu

Sonya George, BS

267-760-7636Sonya.George@PennMedicine.upenn.edu

Principal Investigator:

John Plastaras, MD, PhD

More Information

Sponsor

Abramson Cancer Center at Penn Medicine

Last update posted

Jul 20, 2026

Last verified

Jul, 2026

Keywords

  • Low Dose Radiotherapy
  • Osteoarthritis

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-08. This information was provided to ClinicalTrials.gov by Abramson Cancer Center at Penn Medicine on 2026-07-20.